Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser

Stock Information for Kane Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kane Biotech Inc.

Kane Biotech Announces Third Quarter 2025 Financial Results
Kane Biotech Announces New Private Placement Offering
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
Kane Biotech Announces Second Quarter 2025 Financial Results
Kane Biotech Showcases revyve(TM) Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
Kane Biotech to Present at Advanced Wound Care Summit USA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.